William Faust, MD
Urology · Burlington, MANPI 1730342320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $169, 5.8 times the $29 reported in 2019. That places this record below the midpoint for urology clinicians in MA, where the typical reported total is $1,501.
Across 17 payments — averaging $31.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Laborie Medical Technologies Corp.$96
- Rochester Medical Corporation$87
- AbbVie$62
- Boston Scientific$58
- Teleflex LLC$45
- Ambu Inc.$30
- plus $152 from 6 others
What the payments were for
- Food & beverage$50094%
- Education$296%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Laborie Medical Technologies Corp. | 3 | $96 |
| Rochester Medical Corporation | 1 | $87 |
| AbbVie(2 entities) | 2 | $62 |
| Boston Scientific | 2 | $58 |
| Teleflex LLC | 1 | $45 |
| Ambu Inc. | 1 | $30 |
| Pfizer | 2 | $29 |
| Novo Nordisk | 1 | $28 |
| Urogen Pharma, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Dentsply IH AB | 1 | $17 |
How this compares
$529 in reported general payments places this provider in the 30th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 127 | $101,686 |
| GemtesaVibegron | 38 | $31,423 |
| Tamsulosin Hcl | 735 | $14,451 |
| Trospium Chloride ErTrospium Chloride | 45 | $10,851 |
| Tolterodine Tartrate ErTolterodine Tartrate | 60 | $5,825 |
| Methenamine Hippurate | 95 | $5,639 |
| Finasteride | 374 | $5,257 |
| Potassium Citrate ErPotassium Citrate | 43 | $4,630 |
| Trospium Chloride | 49 | $4,338 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 109 | $2,864 |
| Oxybutynin Chloride ErOxybutynin Chloride | 41 | $1,891 |
| Tadalafil | 16 | $1,116 |
| Estradiol | 14 | $1,033 |
| Terazosin Hcl | 28 | $552 |
| Solifenacin Succinate | 11 | $513 |
Paid to pharmacies, not to this prescriber.
Other urology in Burlington
- Michael CallegariBurlington$53K
- Peris CastanedaBurlington$51K
- Arthur MourtzinosBurlington$43K
- William du CombBurlington$9K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.